Compare NextEra Energy, Inc. (NEE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs BIO-TECHNE Corp — how do they compare? NextEra Energy, Inc. trades at $83 (market cap $174.87B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: NextEra Energy, Inc. is far larger — about 15.4× BIO-TECHNE Corp's market cap, and NextEra Energy, Inc. pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| NEE | TECH | |
|---|---|---|
Market Cap | $174.87B | $11.34B |
Sector | Utilities | Health |
52-Week High | $97.88 | $72.48 |
52-Week Low | $69.83 | $43.31 |
Enterprise Value | $282.20B | $11.36B |
Dividend Yield | 2.97% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $83.83, showing modest daily gains of 0.48% amid a bearish technical outlook. The company demonstrates strong fundamentals with $27.4B revenue and 32.4% net margins in 2025, though recent Q4 2025 earnings missed expectations. Positive developments include securing a $1.9B DOE loan for nuclear plant restart and ongoing investor meetings. Analyst consensus remains strongly bullish with a $100.20 price target, representing 20% upside potential from current levels.
NEE presents a compelling long-term investment case with robust profitability and strategic growth initiatives in renewable energy and nuclear power. However, investors face risks from rising debt levels (47.6% debt-to-asset ratio) and recent technical weakness. The stock's current discount to analyst targets offers opportunity, but requires monitoring of execution on growth projects and debt management.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
